Cyclacel Pharmaceuticals Inc.

0.3502-0.0028-0.79%Vol 18.41K1Y Perf -74.42%
Oct 3rd, 2023 15:59 DELAYED
BID0.3502 ASK0.3600
Open0.3531 Previous Close0.3530
Pre-Market- After-Market-
 - -  - -%
Target Price
16.25 
Analyst Rating
Strong Buy 1.00
Potential %
4.54K 
Finscreener Ranking
 —    -
Insiders Trans % 3/6/12 mo.
-/-/100 
Value Ranking
★★★★     55.46
Insiders Value % 3/6/12 mo.
-/-/100 
Growth Ranking
 —    -
Insiders Shares Cnt. % 3/6/12 mo.
-/-/100 
Income Ranking
 —    -
Price Range Ratio 52W %
5.80 
Earnings Rating
Sell
Market Cap4.43M 
Earnings Date
8th Nov 2023
Alpha-0.05 Standard Deviation0.25
Beta1.13 

Today's Price Range

0.34310.3600

52W Range

0.28001.49

5 Year PE Ratio Range

-0.8000-1.10

Summary:

Neutral

Technical Indicators: Neutral
Moving Averages: Sell
Performance
1 Week
6.97%
1 Month
-11.75%
3 Months
-39.36%
6 Months
-38.08%
1 Year
-74.42%
3 Years
-90.38%
5 Years
-98.77%
10 Years
-99.96%

TickerPriceChg.Chg.%
CYCC0.3502-0.0028-0.79
AAPL172.40-1.3500-0.78
GOOG133.30-1.8700-1.38
MSFT313.39-8.4100-2.61
XOM115.830.20000.17
WFC38.67-0.9400-2.37
JNJ155.340.19000.12
FB196.640.99000.51
GE107.76-1.0300-0.95
JPM142.71-1.0600-0.74
Financial StrengthValueIndustryS&P 500US Markets
6.40
6.40
0.00
0.00
-
Leverage Ratio 1.20
ProfitabilityValueIndustryS&P 500US Markets
-
-6 235.30
-6 220.70
-
-
RevenueValueIndustryS&P 500US Markets
0.00
0.00
-
-
Earnings HistoryEstimateReportedSurprise %
Q02 2023-0.54-0.4418.52
Q01 2023-0.68-0.4730.88
Q04 2022-0.53-0.60-13.21
Q03 2022-0.55-0.4223.64
Q02 2022-0.67-0.4631.34
Q01 2022-0.67-0.4237.31
Q04 2021-0.71-0.5423.94
Q03 2021-0.70-0.5422.86
Earnings Per EndEstimateRevision %Trend
9/2023 QR-0.45-7.14Negative
12/2023 QR-0.3514.63Positive
12/2023 FY-1.65-15.38Negative
12/2024 FY-3.04-2.01Negative
Next Report Date8th Nov 2023
Estimated EPS Next Report-0.45
Estimates Count2
EPS Growth Next 5 Years %-
Volume Overview
Volume18.41K
Shares Outstanding12.64K
Shares Float10.99M
Trades Count53
Dollar Volume6.54K
Avg. Volume59.10K
Avg. Weekly Volume25.44K
Avg. Monthly Volume60.53K
Avg. Quarterly Volume91.34K

Cyclacel Pharmaceuticals Inc. (NASDAQ: CYCC) stock closed at 0.353 per share at the end of the most recent trading day (a -0.48% change compared to the prior day closing price) with a volume of 17.01K shares and market capitalization of 4.43M. Is a component of indices and it is traded on NASDAQ exchange. The company belongs in the Biotechnology industry, Healthcare sector and employs 12 people. Cyclacel Pharmaceuticals Inc. CEO is Spiro Rombotis.

The one-year performance of Cyclacel Pharmaceuticals Inc. stock is -74.42%, while year-to-date (YTD) performance is -47.08%. CYCC stock has a five-year performance of -98.77%. Its 52-week range is between 0.28 and 1.49, which gives CYCC stock a 52-week price range ratio of 5.80%

Cyclacel Pharmaceuticals Inc. currently has a PE ratio of -0.40, a price-to-book (PB) ratio of 0.36, a price-to-sale (PS) ratio of 88.29, a price to cashflow ratio of -, a PEG ratio of -, a ROA of -55.75%, a ROC of -56.85% and a ROE of -62.58%. The company’s profit margin is -%, its EBITDA margin is -6 220.70%, and its revenue ttm is $0.00 , which makes it $0.00 revenue per share.

Of the last four earnings reports from Cyclacel Pharmaceuticals Inc., there were 3 positive earnings surprise and 1 negative earnings surprise. The company has EPS estimate of $-0.45 for the next earnings report. Cyclacel Pharmaceuticals Inc.’s next earnings report date is 08th Nov 2023.

The consensus rating of Wall Street analysts for Cyclacel Pharmaceuticals Inc. is Strong Buy (1), with a target price of $16.25, which is +4 540.21% compared to the current price. The earnings rating for Cyclacel Pharmaceuticals Inc. stock is Sell (calculated from actual period earnings estimates revision (80% weight) and previous period earnings surprise (20% weight)).

Cyclacel Pharmaceuticals Inc. has a dividend yield of -% with a dividend per share of $- and a payout ratio of -%.

Cyclacel Pharmaceuticals Inc. has a Neutral technical analysis rating based on Technical Indicators (ADX : 16.50, ATR14 : 0.04, CCI20 : 84.91, Chaikin Money Flow : -0.31, MACD : -0.02, Money Flow Index : 72.58, ROC : 22.65, RSI : 46.96, STOCH (14,3) : 91.25, STOCH RSI : 0.96, UO : 57.93, Williams %R : -8.75), Simple Moving Averages and Exponential Moving Averages.

Aggregated Insider Trades of Cyclacel Pharmaceuticals Inc. in the last 12-months were:

Analyst RatingsCurrent1 M ago3 M ago
Strong Buy
4 (100.00 %)
4 (100.00 %)
4 (100.00 %)
Moderate Buy
0 (0.00 %)
0 (0.00 %)
0 (0.00 %)
Hold
0 (0.00 %)
0 (0.00 %)
0 (0.00 %)
Moderate Sell
0 (0.00 %)
0 (0.00 %)
0 (0.00 %)
Strong Sell
0 (0.00 %)
0 (0.00 %)
0 (0.00 %)
Summary RatingStrong Buy
1.00
Strong Buy
1.00
Strong Buy
1.00

Cyclacel Pharmaceuticals Inc.

Cyclacel Pharmaceuticals Inc is a clinical-stage biopharmaceutical company which develops targeted medicines for cancer and other proliferative diseases. It develops several families of anticancer drugs that act on the cell cycle, including nucleoside analogs, CDK (cyclin dependent kinase) inhibitors, and PLK (polo-like kinase) inhibitors. The pipeline development programs of the company include CYC065 CDK inhibitor, Sapacitabine and seliciclib, CYC682, CYC140 PLK inhibitor, and CYC202. It earns the majority of its revenue from the United Kingdom.

CEO: Spiro Rombotis

Telephone: +1 908 517-7330

Address: 200 Connell Drive, Berkeley Heights 07922, NJ, US

Number of employees: 12

Bearish or Bullish?
WeekMonthThree MonthsSix Months

Bearish Bullish

50%50%

Bearish Bullish

50%50%

Bearish Bullish

57%43%

Bearish Bullish

59%41%

 

News

Stocktwits